Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial

BACKGROUND: We assessed the cost-effectiveness of single-inhaler fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus FF/VI or UMEC/VI from a Canadian public healthcare perspective, incorporating data from the IMPACT trial in chronic obstructive pulmonary disease (COPD) (NCT02164513)....

Descripción completa

Detalles Bibliográficos
Autores principales: Ismaila, Afisi S, Risebrough, Nancy, Schroeder, Melanie, Shah, Dhvani, Martin, Alan, Goodall, Emma C, Ndirangu, Kerigo, Criner, Gerard, Dransfield, Mark, Halpin, David MG, Han, MeiLan K, Lomas, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890193/
https://www.ncbi.nlm.nih.gov/pubmed/31819401
http://dx.doi.org/10.2147/COPD.S216072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890193/
https://www.ncbi.nlm.nih.gov/pubmed/31819401
http://dx.doi.org/10.2147/COPD.S216072

Ejemplares similares